Filing Flows › Adaptive Biotechnologies (ADPT) › Guidance history
Adaptive Biotechnologies (ADPT) guidance history: what it guided and what it reported
Adaptive Biotechnologies gave guidance in 12 earnings releases on file since Feb 14, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +29.9% against the guided midpoint. Its releases raised guidance 9 times and lowered it 8 times.
Revenue
Met or beat 2 of 2 periods (2 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $255M–$265M (Feb 5, 2026) → raised $260M–$270M (May 5, 2026) → raised $268M–$278M (Jul 29, 2026) → raised $276M–$286M (Nov 4, 2026) | — | to be reported | — |
| FY2025 | $175M–$185M (Feb 11, 2025) → raised $180M–$190M (May 1, 2025) → raised $190M–$200M (Aug 5, 2025) → raised $202M–$207M (Nov 5, 2025) | $277M | above the range | +35.4% |
| FY2024 | $130M–$140M (Feb 14, 2024) → raised $135M–$140M (May 7, 2024) → raised $140M–$145M (Aug 1, 2024) → raised $143M–$145M (Nov 7, 2024) | $179M | above the range | +24.3% |
The latest quarter
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart follows the revenue to costs, profit and cash.
Questions
Does Adaptive Biotechnologies beat its guidance?
Adaptive Biotechnologies gave guidance in 12 earnings releases on file since Feb 14, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +29.9% against the guided midpoint.
How often does Adaptive Biotechnologies raise guidance?
Its earnings releases raised guidance 9 times and lowered it 8 times since Feb 14, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.